肝细胞癌市场:KOL的洞察

本报告提供全球肝细胞癌(HCC)市场相关调查，提供市场概要，以及已通过核准治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

HCC的现在及未来的治疗流程

调查目的

免疫疗法

• 已通过核准医药品
  • TECENTRIQ(Atezolizumab，Roche)+ Avastin(Bevacizumab，Roche)
  • Opdivo(Nivolumab，Bristol Myers Squibb)+ yaboi(Ipilimumab，Bristol Myers Squibb)
  • KEYTRUDA(Pembrolizumab，Merck &Co.)
  • imifinji(Durvalumab，AstraZeneca)+ imujudo(Tremelimumab，AstraZeneca)
• 后期开发平台医药品
  • tisurerizumabu(BeiGene/Novartis)
  • kamurerizumabu(Jiangsu Hengrui)
  • jenperi(dosutarimabu，GSK)+ koborimabu(GSK)
  • ributayo(semipurimabu，Regeneron)

蛋白酪氨酸激?抑制剂

• 已通过核准医药品
  • nekusabaru(Sorafenib，Bayer)
  • LENVIMA(Lenvatinib，Eisai/Merck & Co)
  • Stivarga(Regorafenib，Bayer)
  • kabometikusu(Cabozantinib，Exelixis/Ipsen)

VEGFR抑制剂

• 已通过核准医药品
  • Cyramza(Ramucirumab，Lilly)

其他的作用机制

• 初期阶段的开发平台医药品
  • Fotivda(chibozanibu，AVEO Oncology)
  • namodenoson(Can-Fite BioPharma)
  • GT90001(Kintor Pharmaceutical)
  • ArtemisT细胞疗法(Eureka Therapeutics)
  • MTL-CEBPA(MiNA Therapeutics)
  • fosutorokisashitabinburarupamido/fosutorokusu(Medivir)

HCC治疗的未来趋势与机会

附录

In what new setting could Roche's Tecentriq + Avastin combination consolidate its standard-of-care position for the first-line treatment of immunotherapy-eligible HCC patients? Why are oncologists optimistic about the read out of the EMERALD-2 trial of AstraZeneca's Imfinzi + Roche's Avastin combination and why might EMERALD-3 trial data cause concerns? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

Table of Contents

Executive summary (8)

Current and future treatment algorithm for HCC

Research objectives (2)

Immunotherapy (80)

• Approved drugs (57)
  • Tecentriq (atezolizumab; Roche) + Avastin (bevacizumab; Roche) (12)
  • Opdivo (nivolumab; Bristol Myers Squibb) + Yervoy (ipilimumab; Bristol Myers Squibb) (14)
  • Keytruda (pembrolizumab; Merck & Co.) (19)
  • Imfinzi (durvalumab; AstraZeneca) + Imjudo (tremelimumab; AstraZeneca) (12)
• Late-stage pipeline drugs (23)
  • Tislelizumab (BeiGene/Novartis) (7)
  • Camrelizumab (Jiangsu Hengrui) (5)
  • Jemperli (dostarlimab; GSK) + cobolimab (GSK) (5)
  • Libtayo (cemiplimab; Regeneron) (6)

Tyrosine kinase inhibitors (33)

• Approved drugs (33)
  • Nexavar (sorafenib; Bayer) (8)
  • Lenvima (lenvatinib; Eisai/Merck & Co) (10)
  • Stivarga (regorafenib; Bayer) (9)
  • Cabometyx (cabozantinib; Exelixis/Ipsen) (6)

VEGFR inhibitors (4)

• Approved drugs (4)
  • Cyramza (ramucirumab; Lilly) (4)

Other mechanisms of action (31)

• Early-stage pipeline drugs (31)
  • Fotivda (tivozanib; AVEO Oncology) (6)
  • Namodenoson (Can-Fite BioPharma) (5)
  • GT90001 (Kintor Pharmaceutical) (5)
  • ARTEMIS T-cell therapy (Eureka Therapeutics) (5)
  • MTL-CEBPA (MiNA Therapeutics) (5)
  • Fostroxacitabine bralpamide/fostrox (Medivir) (5)

Future trends and opportunities in HCC treatment (4)

Appendix (7)

• KOL details (7)
  • KOLs from the USA (4)
  • KOLs from Europe (2)